Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Neoadjuvant Treatment of Colon Cancer
- Conditions
- Colon Cancer
- Interventions
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT01108107
- Locations
- 🇩🇰
Dept. of Oncology, Hilleroed Hospital, Hilleroed, Denmark
🇩🇰Department of Oncology, Vejle Hospital, Vejle, Denmark
🇩🇰Department of Oncology, Herlev Hospital, Herlev, Denmark
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
- Conditions
- Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT01099527
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 468
- Registration Number
- NCT01097018
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸TN Oncology, Nashville, Tennessee, United States
Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery
- Conditions
- Colorectal Cancer
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Jeroen Bosch Ziekenhuis
- Target Recruit Count
- 1500
- Registration Number
- NCT01097265
- Locations
- 🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 770
- Registration Number
- NCT01095003
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
- Conditions
- Borderline Ovarian Mucinous TumorStage IA Ovarian Cancer AJCC v6 and v7Recurrent Fallopian Tube CarcinomaStage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Ovarian Mucinous CystadenocarcinomaRecurrent Ovarian CarcinomaStage IC Fallopian Tube Cancer AJCC v6 and v7
- Interventions
- Drug: CarboplatinDrug: CapecitabineBiological: BevacizumabOther: Laboratory Biomarker AnalysisDrug: PaclitaxelDrug: OxaliplatinOther: Quality-of-Life Assessment
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT01081262
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Everolimus and Capecitabine in Patients With Advanced Malignancy
- Conditions
- Advanced Malignancies
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2010-03-03
- Lead Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Target Recruit Count
- 35
- Registration Number
- NCT01079702
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Target Recruit Count
- 35
- Registration Number
- NCT01077986
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
- Conditions
- Triple Negative Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 64
- Registration Number
- NCT01069796
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Hôpital Privé Clairval, Marseille, France
🇫🇷Centre Hospitalier Bretagne Atlantique, Vannes, France
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 240
- Registration Number
- NCT01064999
- Locations
- 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.